Thursday, 23 March 2017
Latest news
Main » Revenue Update on Aratana Therapeutics Inc(NASDAQ:PETX)

Revenue Update on Aratana Therapeutics Inc(NASDAQ:PETX)

21 March 2017

The stock has an average rating of "Buy" and a consensus price target of $9.79. This rating was issued on 9/06/16.

During last 5 trades the stock sticks nearly -20.65%. The company now has an average rating of "Buy" and an average price target of $10.25. The closing price of $25.70 is said to be the result of a growing interest in the chip manufacturing sector, as fellow chip maker AMD will be added to the Standard and Poor's stock index next week. The company earned $0.29 million during the quarter, compared to analyst estimates of $0.80 million. Finally, Stifel Nicolaus cut shares of Aratana Therapeutics from a "buy" rating to a "hold" rating and set a $8.00 price objective for the a research note on Monday, February 6th. (NASDAQ:PETX), with 3 analysts believing it is a strong buy. Barclays Maintains the stock to Overweight on 8/11/16 by stationing a price target of $11.

The stock of Aratana Therapeutics Inc (NASDAQ:PETX) is a huge mover today! Acrospire Investment Management LLC purchased a new stake in shares of Aratana Therapeutics during the third quarter worth approximately $136,000.

For the current quarter, the highest estimate analysts provided is 7.77 Million and the lowest is 950 Million.

More news: Happiest country in the world revealed

Looking forward, for the quarter ending Mar-17, 4 analysts have a mean sales target of 4.24 million. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.

Zacks Investment Research also rated the stock with a value of 1.8.

Aratana Therapeutics, Inc. (NASDAQ:PETX) has the market capitalization of $195.94 Million.

Shares of Cheniere Energy, Inc. While the actual EPS the company reported in the same quarter previous year was -0.52/share.

More news: As Gorsuch Confirmation Hearing Begins, Feinstein Calls Him 'An Extremist'

"In 2016, Aratana distinguished itself as a pioneer in the animal health industry by achieving three FDA approvals for innovative pet therapeutics in a single year", stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics.

Analysts also projected the Maximum, Minimum and Mean Earnings per share Estimate for Next Quarter. Thus the company showed an Earnings Surprise of -52.4 Percent. Broadfin Capital, LLC is the second biggest holder with 4 million shares now valued at 26.53 million whilst Vanguard Group Inc has 2 million shares valued at 12.14 million. The current share price indicate that stock is -50.42% away from its one year high and is moving 36.41% ahead of its 52-week low. The company has a 1 Year high price target of $10.8. The stock is now moving above its 20-Day Simple Moving Average of -26.04% with the 50-Day Simple Moving Average of -26.04 percent. The Moving Average SMA50 is -26.04% while SMA200 is -31.43%.

5 analysts projected Price Targets for Aratana Therapeutics, Inc. Redmond Asset Management LLC now owns 53,887 shares of the biopharmaceutical company's stock valued at $387,000 after buying an additional 215 shares during the last quarter. The stock was last seen -23.45% lower, reaching at $5.32 on March 14, 2017. The Monthly and Yearly performances are -19.39 percent and 15.65 percent respectively. Similar statistics are true for the second largest owner, Broadfin Capital, Llc, which owns 3,695,442 shares of the stock are valued at $25.68 million.

More news: TSMC still considering plans for 3nm chip production